New hope for patients who Can't tolerate standard blood disorder treatment
NCT ID NCT04081220
Summary
This study is testing whether a daily oral medication called IMG-7289 can help control essential thrombocythemia, a condition where the body makes too many platelets. It's for patients who can't tolerate or don't respond to the standard treatment, hydroxyurea. Researchers will check if the drug reduces platelet counts to normal levels and monitor symptoms over 24 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOCYTHEMIA, ESSENTIAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mays Cancer Center
San Antonio, Texas, 78229, United States
Conditions
Explore the condition pages connected to this study.